SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CALO', Girolamo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.661
EU - Europa 4.776
AS - Asia 3.775
SA - Sud America 28
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 11
AF - Africa 2
Totale 31.267
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.614
CN - Cina 1.930
UA - Ucraina 1.380
DE - Germania 929
TR - Turchia 867
IT - Italia 837
SG - Singapore 761
GB - Regno Unito 646
FI - Finlandia 333
SE - Svezia 320
PL - Polonia 87
ID - Indonesia 81
BE - Belgio 64
FR - Francia 54
RU - Federazione Russa 54
VN - Vietnam 49
CA - Canada 46
CZ - Repubblica Ceca 27
IN - India 23
IR - Iran 16
HK - Hong Kong 14
BR - Brasile 13
JP - Giappone 12
CL - Cile 11
NL - Olanda 9
AU - Australia 7
NZ - Nuova Zelanda 7
A2 - ???statistics.table.value.countryCode.A2??? 6
KR - Corea 6
AT - Austria 5
EU - Europa 5
DK - Danimarca 3
GR - Grecia 3
HR - Croazia 3
IE - Irlanda 3
LU - Lussemburgo 3
RO - Romania 3
AR - Argentina 2
BG - Bulgaria 2
CH - Svizzera 2
IQ - Iraq 2
NO - Norvegia 2
YE - Yemen 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BD - Bangladesh 1
BS - Bahamas 1
DZ - Algeria 1
EC - Ecuador 1
EE - Estonia 1
ES - Italia 1
IL - Israele 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
MC - Monaco 1
MD - Moldavia 1
MM - Myanmar 1
MY - Malesia 1
NP - Nepal 1
PE - Perù 1
PH - Filippine 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 31.267
Salva come PNG Salva come JPEG
Città #
Fairfield 3.307
Woodbridge 2.890
Houston 1.957
Ashburn 1.620
Jacksonville 1.591
Ann Arbor 1.518
Chandler 1.392
Seattle 1.339
Wilmington 1.180
Cambridge 1.156
Singapore 563
Izmir 546
Nanjing 455
Princeton 355
Beijing 350
Ferrara 298
San Diego 280
Boardman 263
New York 196
Shanghai 191
Milan 189
Nanchang 137
Shenyang 129
Dearborn 127
Los Angeles 122
Falls Church 92
Warsaw 82
Hebei 81
Jakarta 81
San Mateo 81
Norwalk 78
Santa Clara 78
Jiaxing 75
Bremen 74
Tianjin 74
Changsha 67
Redwood City 64
Mountain View 63
Brussels 61
Munich 58
Jinan 56
Helsinki 49
Addison 48
Auburn Hills 48
Dong Ket 45
London 43
Kunming 42
Washington 42
Zhengzhou 41
Philadelphia 38
Guangzhou 30
Mcallen 30
Montréal 29
Tappahannock 28
Des Moines 27
Ningbo 27
Orange 27
Indiana 26
Bologna 23
Fuzhou 20
Verona 20
Brno 18
Lanzhou 18
Redmond 18
Leawood 17
Padova 17
Augusta 16
Hangzhou 14
Hounslow 12
Taizhou 11
Düsseldorf 10
Toronto 10
Ardabil 9
Bari 8
Changchun 8
Florence 7
Hefei 7
Prescot 7
Walnut 7
Ferrara di Monte Baldo 6
Hong Kong 6
Islington 6
Kilburn 6
Olomouc 6
San Francisco 6
Springfield 6
Amsterdam 5
Chiswick 5
Haikou 5
La Canada Flintridge 5
Monmouth Junction 5
Mumbai 5
Yellow Springs 5
Boston 4
Central District 4
Chicago 4
Colleferro 4
Edinburgh 4
Hanoi 4
Jena 4
Totale 24.318
Salva come PNG Salva come JPEG
Nome #
Chimeric G proteins in fluorimetric calcium assays: Experience with opioid receptors 241
null 205
AGONISTI PIENI E PARZIALI ED ANTAGONISTI DEL RECETTORE PER NOCICETTINA/ORFANINA FQ AD ELEVATA POTENZA” 200
A diastereoselective synthesis of Cebranopadol, a novel analgesic showing NOP/mu mixed agonism 171
A novel and facile synthesis of tetra branched derivatives of nociceptin/orphanin FQ 164
Structural Bacterial Molecules as Potential Candidates for an Evolution of the Classical Concept of Probiotics 162
Characterization of FR 172357, a new non-peptide bradykinin B2 receptor antagonist, in human, pig and rabbit preparations 162
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 160
Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide. 146
Human vascular kinin receptors of the B-2 type characterized by radioligand binding 144
Kinin B-1 and B-2 receptors in pig vessels: characterization of two monoreceptor systems 143
N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands 141
Structure activity studies of nociceptin/orphanin FQ(1–13)-NH2 derivatives modified in position 5 140
[Dmt(1) ]N/OFQ(1-13)-NH(2) , a potent nociceptin/orphanin FQ and opioid receptor universal agonist. 140
[Nphe(1),Arg(14),Lys(15)]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor 139
Tryptophan replacement in the nociceptin/orphanin FQ receptor ligand Ac-RYYRWK-NH2 136
A new selective antagonist of the nociceptin receptor 136
Emergency admissions of opioid drug-abusers for overdose. A chronobiological study of enhanced risk 135
Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic- versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands 135
Behavioural phenotypic characterization of CD-1 mice lacking the neuropeptide S receptor 134
Pharmacological profile of nociceptin/orphanin FQ receptors interacting with G-proteins and β-arrestins 2 134
Intrathecal administration of nociceptin/orphanin FQ receptor agonists in rats: A strategy to relieve chemotherapy-induced neuropathic hypersensitivity 134
Conformation-activity relationship of neuropeptide S and some structural mutants: Helicity affects their interaction with the receptor 134
Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity 133
Pharmacological characterization of nociceptin receptor: an in vitro study 133
Anxiolytic- and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze. 132
Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptor 132
Nociceptin/orphanin FQ induces simultaneously anxiolytic and amnesic effects in the mouse elevated T-maze task. 131
Characterisation of the novel mixed Mu-NOP peptide ligand dermorphin-N/OFQ (DeNo) 131
[D-Pen(p-tBuBzl)5]NPS, a novel ligand for the neuropeptide S receptor: structure activity and pharmacological studies 130
A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials 130
Ring size in cyclic endomorphin-2 analogs modulates receptor binding affinity and selectivity 129
In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor 128
In vitro pharmacological characterisation of a novel cyclic nociceptin/orphanin FQ analogue c[Cys(7,10)]N/OFQ(1-13)NH2 128
A new ligand for the urotensin II receptor 128
Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt(1)]N/OFQ(1-13) 128
Modulation of the NOP receptor signaling affects resilience to acute stress 128
UFP-112 a Potent and Long-Lasting Agonist Selective for the Nociceptin/Orphanin FQ Receptor 127
Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems 127
Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist 126
Pharmacology of [Tyr(1)]nociceptin analogs: receptor binding and bioassay studies 126
Synthesis and biological activity of human neuropeptide S analogues modified in position 2 126
Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111 126
Structure-and conformation-Activity studies of nociceptin/orphanin FQ receptor dimeric ligands 125
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease 123
Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction 123
AMPA receptor activation regulates the glutamate metabotropic receptor stimulated phosphatidylinositol turnover in human cerebral cortex slices 123
Cardiovascular effects of nociceptin in unanesthetized mice 122
Antidepressant activity of nociceptin/orphanin FQ receptor antagonists in the mouse learned helplessness 122
Effects of vasoactive agents in healthy and diseased human saphenous veins 122
Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test 122
The Importance of Ligand-Receptor Conformational Pairs in Stabilization: Spotlight on the N/OFQ G Protein-Coupled Receptor 121
Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs. 120
[(t)Bu-d-Gly(5)]NPS, a pure and potent antagonist of the neuropeptide S receptor: In vitro and in vivo studies 119
UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ; Behavioral and electrophysiological studies in mice 119
[Nphe(1)]nociceptin-(1-13)-NH2 antagonizes nociceptin effects in the mouse colon 118
Electrocardiographic alterations as a result of acute intoxication with fluvoxamine and pipamperone 118
Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11) 117
Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist 117
Selective breeding for high anxiety introduces a synonymous SNP that increases neuropeptide s receptor activity 117
Synthesis of mixed MOR/KOR efficacy cyclic opioid peptide analogs with antinociceptive activity after systemic administration 117
In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403 117
Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: Pharmacological and genetic evidences 116
[Nphe(1)]N/OFQ-(1-13)-NH2 is a competitive and selective antagonist at nociceptin/orphanin FQ receptors mediating K+ channel activation in rat periaqueductal gray slices 116
Effects of neuropeptide S on seizures and oxidative damage induced by pentylenetetrazole in mice. 116
Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24. 116
Pharmacological characterization of the nociceptin receptor mediating hyperphagia: identification of a selective antagonist 115
Effects of chronic nociceptin/orphanin FQ exposure on cAMP accumulation and receptor density in Chinese, hamster ovary cells expressing human nociceptin/orphanin FQ receptors 115
Further studies on nociceptin-related peptides: Discovery of a new chemical template with antagonist activity on the nociceptin receptor 115
Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 5: Identification of Potent and Pure Neuropeptide S Receptor Antagonists. 115
Address and message sequences for the nociceptin receptor: A structure-activity study of nociceptin-(1-13)-peptide amide 115
Dmt-Tic-NH-CH2-Bid (UFP-502), a potent DOP receptor agonist: In vitro and in vivo studies 114
Actual concept of "probiotics": is it more functional to science or business? 114
Pharmacological characterization of tachykinin tetrabranched derivatives 113
Role of nociceptin/orphanin FQ receptors in the decrease of mucosal mast cells caused by acute stress in the rat colon. 112
In vitro and in vivo pharmacological characterization of the novel neuropeptide S receptor ligands QA1 and PI1 112
Structure-activity study at positions 3 and 4 of human neuropeptide S. 112
Assessment of the activity of a novel nociceptin/orphanin FQ analogue at recombinant human nociceptin/orphanin FQ receptors expressed in Chinese hamster ovary cells 111
[Nphe(1)]nociceptin-(1-13)NH2 selectively antagonizes nociceptin effects in the rabbit isolated ileum 111
Structure-activity relationship study on Tyr9 of urotensin-II(4-11): identification of a partial agonist of the UT receptor. 110
Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies 110
Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands 110
null 110
Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay 109
Nociceptin/orphanin FQ receptor knockout rats: in vitro and in vivo studies. 109
In vitro and in vivo pharmacological characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant 109
Sudden death from pulmonary thromboembolism: chronobiological aspects 108
Nociceptin/orphanin FQ inhibits ischaemia-induced glutamate efflux from rat cerebrocortical slices 108
Studies on the antinociceptive effect of [Nphe(1)]nociceptin(1-13)NH2 in mice 108
Pharmacological profile of hemokinin 1: a novel member of the tachykinin family 108
Inhibitory effect of NMDA receptor activation on quisqualate-stimulated phosphatidylinositol turnover in the human cerebral cortex 108
Desensitisation of native and recombinant human urotensin-II receptors. 108
[Arg(14), Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies 108
Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. 107
Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents 107
Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist 107
Neuropeptide S receptor ligands: a patent review (2005-2016) 107
Urotensin II stimulates plasma extravasation in mice via UT receptor activation 107
Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands 106
Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux 106
Totale 12.605
Salva come PNG Salva come JPEG
Categoria #
all - tutte 143.505
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.646
Totale 146.151
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.874 0 0 0 1.078 558 872 748 783 660 653 331 191
2020/20214.830 378 445 264 570 307 489 167 567 154 634 577 278
2021/20223.644 144 369 312 217 203 190 217 236 156 302 313 985
2022/20233.455 379 160 114 414 572 485 177 315 470 21 196 152
2023/20241.781 196 229 88 50 99 310 74 142 35 30 53 475
2024/20251.017 183 203 631 0 0 0 0 0 0 0 0 0
Totale 31.736